At Quidel, we are committed to conducting our business in accordance with all applicable laws, rules, and regulations, and the highest ethical standards. This section includes documents regarding the Company's corporate governance practices, evidencing the Company's commitment to sound principles of corporate governance.

Quidel’s Comprehensive Compliance Program, Code of Business Conduct and Ethics, and Annual Written Declaration may be obtained by calling 800-874-1517.

Executive Management


Douglas C. Bryant, President and Chief Executive Officer

Douglas C. Bryant became President and Chief Executive Officer on March 1, 2009. Prior to joining Quidel, Mr. Bryant served as Executive Vice President and Chief Operating Officer at Luminex Corporation, managing its Bioscience Group, Luminex Molecular Diagnostics (Toronto), manufacturing, R&D, technical operations, and commercial operations. From 1983 to 2007, he held various worldwide commercial operations positions with Abbott Laboratories including, among others: Vice President of Abbott Vascular for Asia/Japan, Vice President of Abbott Molecular Global Commercial Operations and Vice President of Abbott Diagnostics Global Commercial Operations. Earlier in his career with Abbott, Mr. Bryant was Vice President of Diagnostic Operations in Europe, the Middle East and Africa, and Vice President of Diagnostic Operations Asia Pacific. Mr. Bryant holds a B.A. in Economics from the University of California at Davis.


Randall J. Steward, Chief Financial Officer

Randy Steward became Chief Financial Officer of Quidel Corporation in November 2011. Mr. Steward has more than 30 years of experience in executive management and finance. Prior to joining Quidel, Mr. Steward served as Chief Financial Officer for Navilyst Medical, Inc, a medical device company based in Massachusetts. From 2008 to January 2011, Mr. Steward was Chief Operating Officer for SeQual Technologies, Inc. a San Diego-based medical device company, where he was responsible for all aspects of Engineering, Manufacturing, Finance, and Information Systems. He played a significant role in working with the Board of Directors to successfully complete a sale of the business to a strategic partner. Prior to SeQual Technologies, Mr. Steward spent 11 years with Spectrum Brands as Executive Vice President and CFO. During those 11 years Spectrum Brands grew into a $2 billion publicly traded consumer products company. Mr. Steward holds a B.B.A. in Accounting from Southern Methodist University. He is also a Certified Public Accountant and a member of AICPA.


Robert J. Bujarski, Chief Operating Officer

Robert Bujarski became our Chief Operating Officer in September 2020. Previously, Mr. Bujarski was our Senior Vice President for North America Commercial Operations from July 2019-September 2020, Senior Vice President, General Counsel from August 2009 to September 2020, Senior Vice President, Business Development from August 2009 to July 2019 and General Counsel and Vice President from July 2005 to March 2007. Prior to joining Quidel, Mr. Bujarski was an associate attorney with the law firm of Gibson, Dunn & Crutcher LLP in its transactions practice group from October 2001 to July 2005. Mr. Bujarski received his B.A. degree in 1991 from the University of Arizona and his law degree in 2001 from the University of Arizona.


Michael D. Abney, Jr., SVP, North American Sales & Distribution

Michael D. Abney, Jr. became Senior Vice President, North American Sales & Distribution in September 2020. Previously, Mr. Abney was our Senior Vice President, Distribution from January 2015 to September 2020. Prior to joining Quidel, Mr. Abney served as Vice President, Channel and Distribution for ConvaTec. He has also held a number of operational and financial positions at PSS World Medical, from 1989 to 2013, most recently Vice President, Supplier Management. Mr. Abney holds a bachelor’s degree in Finance from the University of Florida.


Ratan Borkar, SVP, International Commercial Operations

Ratan Borkar, became our Senior Vice President, International Commercial Operations in October 2017. He joined Quidel in May 2009 as Vice President, Business Development. In February 2012, Mr. Borkar moved into the role of VP, International Commercial Operations. Prior to Quidel, Mr. Borkar had a career in Investment Banking, where he most recently worked at J.P. Morgan as Vice President in the Healthcare Investment Banking Group, advising companies in the diagnostics, life sciences and clinical research areas. Mr. Borkar started his career at KPMG and is a Chartered Accountant. Mr. Borkar has an MBA from the University of Michigan’s Ross School of Business, where we was an Alan Gelband Scholar. Mr. Borkar received his Bachelor of Commerce from the University of Mumbai.


William J. Ferenczy, SVP, Cardiometabolic Business Unit

William Ferenczy became Senior Vice President, Cardiometabolic Business Unit in April 2020. He joined Quidel in 2011 as Senior Director, US Marketing and subsequently held positions as Senior Director and General Manager, Savanna and Vice President, Strategy and Global Product Management. Mr. Ferenczy has over 30 years of experience leading product launches and market development across a wide range of diagnostic companies including Abbott Diagnostics, Biosite Diagnostics, Nanosphere and Inovise Medical. Early in his career, he held several manufacturing management positions of increasing responsibility at Abbott Hospital Products and General Medical Manufacturing. Mr. Ferenczy hold a B.S. in Pre-professional Studies from the University of Notre Dame.


Karen Gibson, SVP, Digital Health

Karen Gibson became our Senior Vice President, Digital Health in June 2021. Ms. Gibson joined Quidel in April, 2015 as Vice President, Information Systems. In July 2017, Ms. Gibson took on additional responsibilities as the Integration Leader for the Triage® cardiovascular and toxicology businesses acquired from Abbott. This included building out shared service and supply chain operations in Europe and China, while simultaneously integrating our Manufacturing, Quality, Regulatory, and R&D organizations. Prior to joining Quidel, Ms. Gibson has a history of global operational and technology leadership positions within the life sciences industry including SVP and Chief Information Officer for McKesson Specialty Health, SVP and Chief Information Officer for Life Technologies, as well as senior roles within General Electric and Johnson & Johnson. Ms. Gibson received her B.S. from Purdue University in Computer Technology, and an MBA from Ohio University.


Michelle A. Hodges, SVP, General Counsel

Michelle Hodges became our SVP, General Counsel in December 2020. Prior to joining Quidel, Ms. Hodges was a corporate lawyer with the law firm of Gibson, Dunn & Crutcher LLP from December 1996 through November 2020, most recently as a partner from 2005. Ms. Hodges received her B. Hort. Sci. degree from Massey University, New Zealand, and her J.D. and M.B.A. from UCLA.


Werner Kroll, SVP, Research & Development

Werner Kroll became SVP, Research & Development for Quidel in May 2014. Dr. Kroll is responsible for all aspects of research and development of the Company’s immunoassay and molecular products, from initial concept through to manufacturability. Prior to joining Quidel, Dr. Kroll was Vice President and Global Head of Research and Innovation for Novartis Molecular Diagnostics/Codiagnostics. He has also held senior positions at Novartis Pharmaceuticals, Bayer Diagnostics and Bayer Pharmaceuticals, and AGFA. In addition, Dr. Kroll serves on the board of directors of the European Personalised Medicine Association (EPEMED). Dr. Kroll received his doctorate in Physiological Chemistry from the University of Marburg.


Tamara Ranalli, SVP, Molecular Business Unit

Dr. Tamara Ranalli became the Senior Vice President of the Molecular Business Unit in August of 2020. Prior to this position at Quidel, she held several roles at Quidel most recently as Vice President of Marketing for North America and has been with the organization since 2010. Before joining Quidel, Dr. Ranalli was the Director of Business Development at BioHelix Corporation where she was instrumental in both the development of the novel isothermal technology used in the AmpliVue and Solana platforms as well as in establishing the collaboration between BioHelix and Quidel that led to the eventual acquisition of BioHelix in 2013. Dr. Ranalli holds a BA degree in Biology from Cornell University, a Ph.D in Biochemistry from University of Rochester School of Medicine and completed a post-doctoral fellowship in Cancer Genetics at Roswell Park Cancer Institute.

Edward K. Russell, SVP, Business Development

Edward K. Russell became SVP, Business Development in July 2019, after being Quidel's Senior Vice President of North America Commercial Operations in October 2015. Prior to joining Quidel, Mr. Russell was with Life Technologies/Thermo Fisher where he most recently was responsible for leading their North American Commercial team, a $1B operation. Prior to that, Mr. Russell held positions that include responsibility for Life’s Global Services & Support business, served as President & GM of Life's Japanese operations, and led the Sales Operations function. Mr. Russell's industry experience is varied and includes high level commercial and senior leadership roles at Fedex Kinko’s and Mobil Oil. Mr. Russell started his private sector career in an MBA leadership development program for Toyota/Lexus after serving as an officer in the U.S. Coast Guard, is a graduate of the U.S. Coast Guard Academy, and also holds an MBA from the Wharton School of Business, University of Pennsylvania.

Board of directors

Kenneth F. Buechler, Chairman of the Board, Founder, Former President and CSO, Biosite inc.

Douglas C. Bryant, President and Chief Executive Officer Quidel Corporation

Edward L. Michael, Managing Partner and Co-Founder of LionBird Ventures

Kathy P. Ordoñez, Former officer of Pacific Biosciences, RainDance Technologies, Inc., Quest Diagnostics, Inc., Celera, and Hoffmann-La Roche

Mary Lake Polan M.D, Clinical Professor Yale University School of Medicine

Ann D. Rhoads, Former Chief Financial Officer, Forty Seven, Inc.

Charles P. Slacik, Former Senior Vice President and Chief Financial Officer for Beckman Coulter, Inc.

Matthew W. Strobeck, Managing Partner of Birchview Capital

Kenneth J. Widder, Former General Partner, Lattrell Venture Partners, LVP Life Science Ventures

Joseph D. Wilkins Jr., Partner, TRG Healthcare

Committee Composition


Quidel does not undertake any animal testing or outsource any animal testing to any third party.